The weekly litigation news digest is live. Subscribe now

Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate

Patent No. EP2139494 (titled "Pharmaceutical Formulations Containing Dapagliflozin Propylene Glycol Hydrate") was filed by Astrazeneca on Mar 21, 2008. The application was issued on Mar 11, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2139494

ASTRAZENECA
Application Number
EP08732695A
Filing Date
Mar 21, 2008
Status
Granted And Under Opposition
Feb 7, 2020
Publication Date
Mar 11, 2020
External Links
Slate, Register, Google Patents